GO:0046496 nicotinamide nucleotide metabolic process: NAD+ Biosynthesis and Salvage, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046496 describes all chemical reactions and pathways involving nicotinamide nucleotides, including NAD+, NADH, NADP+ and NADPH.
• The term covers de novo biosynthesis from tryptophan, the Preiss-Handler pathway from nicotinic acid, and salvage pathways from nicotinamide and nicotinamide riboside.
• Nicotinamide nucleotide metabolism is central to redox balance, mitochondrial function, DNA repair, calcium signaling and stem cell maintenance.
• Acute kidney injury in humans is linked to impaired de novo NAD+ biosynthesis, making this pathway a clinically relevant biomarker and therapeutic target.
• Oral nicotinamide riboside is bioavailable and can elevate NAD+ in human tissues, supporting its use in clinical and translational studies.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to dissect causal roles of genes in this pathway.
Description
Nicotinamide nucleotide metabolic process (GO:0046496) is the biological process that encompasses all chemical reactions and pathways involving nicotinamide nucleotides, which are nucleotides containing a combined nicotinamide moiety. These molecules include the oxidized and reduced forms of nicotinamide adenine dinucleotide (NAD+ and NADH) and its phosphorylated counterpart (NADP+ and NADPH), which serve as essential redox carriers and signaling molecules in every cell. The pathway is fundamental to energy metabolism, oxidative stress defense, and post-translational modifications such as ADP-ribosylation and deacetylation. Research into GO:0046496 has accelerated because NAD+ levels decline with age and in multiple disease states, and because boosting NAD+ through precursors such as nicotinamide riboside can improve mitochondrial function and stem cell activity in animal models. In humans, impaired de novo NAD+ biosynthesis is associated with acute kidney injury, highlighting the clinical importance of this metabolic process. Moreover, recent work shows that phages can reconstitute NAD+ to counter bacterial immunity, revealing unexpected roles for nicotinamide nucleotide metabolism in host-pathogen interactions. For researchers, understanding GO:0046496 requires integrating enzymology, flux analysis, and genetic models. The pathway is highly compartmentalized and regulated, with distinct enzymes for biosynthesis, salvage, and catabolism. This article provides a structured overview of the process, its key genes, disease links, and the CRISPR-based methods used to study it.
nicotinamide nucleotide metabolic process At A Glance
| GO ID | GO:0046496 |
|---|---|
| GO term | nicotinamide nucleotide metabolic process |
| Ontology | biological_process |
| Synonym | nicotinamide nucleotide metabolism |
| Major function | Biosynthesis, salvage, interconversion and catabolism of NAD+, NADH, NADP+ and NADPH |
| Key precursors | Tryptophan, nicotinic acid, nicotinamide, nicotinamide riboside |
| Subcellular locations | Cytosol, mitochondria, nucleus |
| Related processes | Redox balance, mitochondrial function, DNA repair, calcium signaling, aging |
What Is GO:0046496?
GO:0046496, nicotinamide nucleotide metabolic process, is defined by the Gene Ontology as the chemical reactions and pathways involving nicotinamide nucleotides, any nucleotide that contains combined nicotinamide. In practice, this includes the biosynthesis, interconversion, salvage, and degradation of NAD+, NADH, NADP+, and NADPH, as well as the regulation of their intracellular concentrations.
Why Is nicotinamide nucleotide metabolic process Important in Cell Biology?
Nicotinamide nucleotide metabolism is essential for life because NAD+ and NADP+ are required for hundreds of oxidoreductase reactions, and their reduced forms carry electrons in catabolic and anabolic pathways. Beyond redox, NAD+ is consumed by sirtuins, PARPs, and CD38, linking this metabolic process directly to gene regulation, DNA repair, and immune responses. Consequently, dysregulation of GO:0046496 contributes to aging, metabolic disorders, kidney injury, neurodegeneration, and cancer, making it a high-priority area for therapeutic development.
• Maintains cellular redox homeostasis through NAD+/NADH and NADP+/NADPH ratios.
• Supports mitochondrial oxidative phosphorylation and ATP production.
• Provides substrate for sirtuins and PARPs, influencing epigenetics and DNA repair.
• Declines with age and in age-related diseases, making it a target for interventions.
• Impaired de novo NAD+ biosynthesis is a feature of human acute kidney injury.
• Nicotinamide riboside supplementation can elevate NAD+ in human muscle and blood.
• Phages exploit NAD+ reconstitution to overcome bacterial immunity, showing evolutionary importance.
• NAD(P)(H) catabolism generates signaling molecules such as ADP-ribose and cyclic ADP-ribose.
• Dysregulation is linked to cancer, neurodegeneration, and metabolic syndrome.
• CRISPR models enable causal testing of pathway genes in disease contexts.
What Happens During nicotinamide nucleotide metabolic process?
De novo biosynthesis from tryptophan
In simple terms: The body can build NAD+ from scratch starting with the amino acid tryptophan.
The de novo pathway converts tryptophan through a series of enzymatic steps to nicotinic acid mononucleotide (NaMN), which is then converted to NAD+ via the Preiss-Handler pathway. In humans, this pathway is particularly important in the kidney and liver, and its impairment is associated with acute kidney injury. Key enzymes include IDO1, TDO2, KYNU, and QPRT, which are regulated by inflammatory and metabolic signals.
Preiss-Handler pathway from nicotinic acid
In simple terms: Nicotinic acid (vitamin B3) is converted to NAD+ through a short salvage route.
The Preiss-Handler pathway starts with nicotinic acid, which is converted to NaMN by NAXD or NAXE, then to nicotinic acid adenine dinucleotide (NaAD) by NMNAT, and finally to NAD+ by NAD synthase. This pathway is a major source of NAD+ in tissues that lack de novo synthesis capacity.
Salvage from nicotinamide and nicotinamide riboside
In simple terms: Cells recycle nicotinamide and nicotinamide riboside back into NAD+.
The salvage pathway recycles nicotinamide (NAM) to NMN by NAMPT, and nicotinamide riboside (NR) to NMN by NRK1/2, with NMN then converted to NAD+ by NMNAT1-3. This pathway is critical for maintaining NAD+ levels in response to stress and is the target of supplements such as NR and NMN. Oral NR is bioavailable and can raise NAD+ in human tissues.
NADP+ synthesis and redox interconversion
In simple terms: NAD+ can be converted to NADP+ for use in biosynthesis and antioxidant defense.
NAD+ is phosphorylated to NADP+ by NAD kinases, and NADP+ is reduced to NADPH by enzymes such as glucose-6-phosphate dehydrogenase and malic enzyme. NADPH is essential for reductive biosynthesis and for regenerating reduced glutathione, linking this process to oxidative stress resistance.
Catabolism and signaling
In simple terms: NAD+ is broken down to generate signaling molecules and regulate its own levels.
NAD+ is consumed by CD38, PARPs, and sirtuins, producing ADP-ribose, cyclic ADP-ribose, and nicotinamide. These catabolic reactions are not merely degradative; they generate second messengers for calcium signaling and regulate protein function through ADP-ribosylation and deacetylation. The balance between biosynthesis and catabolism determines net NAD+ availability.
Key Genes Involved in GO:0046496 nicotinamide nucleotide metabolic process
The following genes encode core enzymes and regulators of nicotinamide nucleotide metabolic process, with established roles in NAD+ biosynthesis, salvage, and catabolism.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NAMPT | Rate-limiting enzyme in NAD+ salvage from nicotinamide | Target for NAD+ modulation in aging and metabolic disease |
| NMNAT1 | Converts NMN to NAD+ in nucleus and cytosol | Mutations cause retinal degeneration; key for nuclear NAD+ |
| NMNAT2 | Neuronal NMNAT isoform | Essential for axon survival; linked to neurodegeneration |
| NMNAT3 | Mitochondrial NMNAT isoform | Regulates mitochondrial NAD+ and metabolism |
| NRK1 | Phosphorylates nicotinamide riboside to NMN | Mediates effects of NR supplementation |
| NRK2 | Muscle-specific NR kinase | Involved in NR-induced NAD+ elevation in muscle |
| NADSYN1 | Glutamine-dependent NAD+ synthetase | Final step of Preiss-Handler and de novo pathways |
| QPRT | Quinolinate phosphoribosyltransferase | De novo pathway enzyme; linked to kidney injury |
| IDO1 | Tryptophan 2,3-dioxygenase | First step of de novo NAD+ synthesis; immune regulation |
| TDO2 | Tryptophan 2,3-dioxygenase | Alternative first step of de novo pathway |
| KYNU | Kynureninase | De novo pathway; mutations cause NAD+ deficiency |
| NAXD | NAD(P)HX dehydratase | Repairs damaged NADH; mutations cause neurodegeneration |
| NAXE | NAD(P)HX epimerase | Repairs damaged NADH; mutations cause encephalopathy |
| CD38 | NAD+ glycohydrolase | Major NAD+ consumer; target for NAD+ elevation |
| PARP1 | Poly(ADP-ribose) polymerase | Consumes NAD+ for DNA repair; linked to cancer and aging |
| SIRT1 | NAD+-dependent deacetylase | Links NAD+ to epigenetics and metabolism |
| SIRT3 | Mitochondrial NAD+-dependent deacetylase | Regulates mitochondrial function and ROS |
| ACMSD | Aminocarboxymuconate semialdehyde decarboxylase | Regulates de novo pathway flux |
How Is nicotinamide nucleotide metabolic process Regulated?
Nicotinamide nucleotide metabolism is regulated at multiple levels. Transcriptional control of NAMPT by circadian clock components and inflammatory signals influences NAD+ availability. Enzymatic activity is feedback-inhibited by NAD+ and regulated by substrate availability, while catabolic enzymes such as CD38 and PARP1 are induced by stress and inflammation, increasing NAD+ consumption. Post-translational modifications, including phosphorylation and acetylation, modulate enzyme activity. In addition, compartmentalization between cytosol, mitochondria, and nucleus creates distinct NAD+ pools that are differentially regulated.
nicotinamide nucleotide metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| QPRT | Acute kidney injury | Kidney organoids with QPRT knockout |
| NAMPT | Metabolic syndrome and aging | Inducible NAMPT knockout mice |
| NMNAT2 | Neurodegeneration | Neuronal-specific NMNAT2 knockout |
| CD38 | Inflammation and NAD+ decline | CD38 knockout mice |
| NAXD | Neurodegeneration with brain edema | Patient fibroblasts and NAXD knockout cells |
Acute kidney injury and de novo NAD+ biosynthesis
Impaired de novo NAD+ biosynthesis is observed in humans with acute kidney injury, and urinary quinolinate levels can predict injury severity. This links GO:0046496 directly to renal disease and suggests that NAD+ precursors may have therapeutic potential.
Aging and mitochondrial dysfunction
NAD+ levels decline with age, and repletion with nicotinamide riboside improves mitochondrial function and extends lifespan in mice. This has spurred interest in targeting salvage pathway enzymes such as NAMPT and NRK1 to counteract age-related decline.
Neurodegeneration
Mutations in NMNAT2 and NAXD/NAXE cause severe neurological disorders, underscoring the importance of nicotinamide nucleotide metabolism for neuronal survival. NAD+ depletion contributes to axonal degeneration and neurodegeneration in multiple models.
Cancer and immune evasion
NAD+ is required for PARP-mediated DNA repair and for sirtuin activity, and cancer cells often upregulate salvage enzymes to sustain proliferation. Phages can reconstitute NAD+ to counter bacterial immunity, illustrating how NAD+ metabolism influences host-pathogen interactions.
From nicotinamide nucleotide metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NAMPT reduce cellular NAD+? | NAMPT knockout cell line (CRISPR) |
| Does a point mutation in NMNAT1 affect catalytic activity? | NMNAT1 point-mutation knock-in |
| Can tagged NMNAT3 reveal mitochondrial localization? | NMNAT3 knock-in with FLAG tag |
| Does NRK1 overexpression increase NAD+? | NRK1 overexpression cell line |
| Does CD38 deletion elevate NAD+ in vivo? | CD38 knockout mouse |
| Does QPRT loss impair de novo NAD+ synthesis? | QPRT knockout kidney organoids |
How to Study the nicotinamide nucleotide metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS metabolomics | NAD+, NADH, NADP+, NADPH, intermediates | Quantify pathway metabolites |
| 13C isotope tracing | Flux through de novo and salvage pathways | Determine precursor contribution |
| CRISPR knockout screens | Genes required for NAD+ homeostasis | Identify novel regulators |
| Western blot | Protein levels and modifications | Assess PARP and sirtuin activity |
| Co-immunoprecipitation | Protein-protein interactions | Map enzyme complexes |
| NAD+ biosensor imaging | Real-time NAD+ dynamics | Live-cell compartmental analysis |
| qPCR / RNA-seq | Transcript levels of pathway genes | Evaluate transcriptional regulation |
| Enzymatic activity assays | Catalytic activity of NAMPT, NMNAT, etc. | Validate point mutations |
Metabolomics and flux analysis
Targeted metabolomics using LC-MS/MS can quantify NAD+, NADH, NADP+, NADPH, and intermediates such as NMN and NaMN. Isotope tracing with 13C-tryptophan or 13C-nicotinamide enables flux analysis through de novo and salvage pathways.
Genetic screens and CRISPR libraries
Genome-wide CRISPR knockout screens can identify genes required for NAD+ homeostasis and resistance to NAD+ depletion. Focused libraries targeting metabolic enzymes are useful for dissecting pathway redundancy.
Protein interaction and modification assays
Co-immunoprecipitation and proximity labeling can reveal interactions among NAMPT, NMNATs, and NRKs. Western blotting for ADP-ribosylation and acetylation assesses downstream effects of NAD+ levels.
Imaging and reporter systems
Genetically encoded NAD+ sensors such as FiNad allow real-time monitoring of NAD+ dynamics in live cells. Fluorescent tagging of enzymes enables subcellular localization studies.
How CRISPR Can Be Used to Study GO:0046496 nicotinamide nucleotide metabolic process
Knockout
CRISPR knockout of NAMPT, NMNAT1, or NRK1 can abolish specific NAD+ synthesis routes, revealing their contribution to total NAD+ and cell viability. Knockout models are also used to test synthetic lethality with NAD+-lowering drugs.
Point Mutation
Point mutations in catalytic residues of NMNAT1 or NADSYN1 can dissect enzyme mechanism and identify loss-of-function variants associated with disease. CRISPR prime editing or homology-directed repair enables precise mutation introduction.
Knock-in
Knock-in of epitope tags or fluorescent reporters at endogenous loci allows tracking of enzyme localization and dynamics without overexpression artifacts. This is particularly useful for compartment-specific NAD+ studies.
Overexpression
Overexpression of NRK1 or NAMPT can boost NAD+ levels and test sufficiency in rescuing phenotypes such as mitochondrial dysfunction or aging-related decline. Inducible overexpression systems provide temporal control.
How EDITGENE Supports nicotinamide nucleotide metabolic process Research
Researchers studying nicotinamide nucleotide metabolic process-related genes often need to determine whether a candidate gene is causally involved in NAD+ regulation, disease progression, or therapeutic response. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for nicotinamide nucleotide metabolic process research.
Frequently Asked Questions About nicotinamide nucleotide metabolic process
What is GO:0046496?
GO:0046496 is the Gene Ontology term for nicotinamide nucleotide metabolic process, covering all reactions and pathways involving NAD+, NADH, NADP+ and NADPH.
What genes are involved in nicotinamide nucleotide metabolic process?
Key genes include NAMPT, NMNAT1-3, NRK1/2, NADSYN1, QPRT, IDO1, TDO2, KYNU, CD38, PARP1, and SIRT1-3.
Why is NAD+ important for health?
NAD+ is essential for redox reactions, mitochondrial function, DNA repair, and sirtuin activity, and its decline is linked to aging and disease.
How is NAD+ synthesized in cells?
NAD+ is synthesized de novo from tryptophan, via the Preiss-Handler pathway from nicotinic acid, and by salvage from nicotinamide and nicotinamide riboside.
What is the role of NAMPT in NAD+ metabolism?
NAMPT is the rate-limiting enzyme in the salvage pathway that converts nicotinamide to NMN, a direct precursor of NAD+.
Can nicotinamide riboside increase NAD+ in humans?
Yes, oral nicotinamide riboside is bioavailable and has been shown to elevate NAD+ levels in human muscle and blood.
What diseases are linked to impaired NAD+ biosynthesis?
Impaired de novo NAD+ biosynthesis is associated with acute kidney injury, and NAD+ decline is linked to neurodegeneration and metabolic disorders.
How do researchers study nicotinamide nucleotide metabolism?
Common methods include LC-MS/MS metabolomics, isotope tracing, CRISPR screens, and NAD+ biosensor imaging.
What CRISPR models are used for NAD+ pathway genes?
Knockout, point-mutation, knock-in, and overexpression models are used to test gene function and causality.
Is NAD+ metabolism a therapeutic target?
Yes, targeting NAD+ metabolism is being explored for aging, kidney injury, neurodegeneration, and cancer.
Conclusion
GO:0046496 nicotinamide nucleotide metabolic process is a central metabolic hub that sustains redox balance, energy production, and signaling. Its dysregulation contributes to a wide range of human diseases, and interventions such as nicotinamide riboside show promise in restoring NAD+ levels. Continued research using CRISPR models and advanced metabolomics will clarify causal mechanisms and guide therapeutic development.
References
- 1. Migaud ME et al.. 2024. Regulation of and challenges in targeting NAD(+) metabolism.. Nat Rev Mol Cell Biol 25(10):822-840 PMID: 39026037
- 2. Poyan Mehr A et al.. 2018. De novo NAD(+) biosynthetic impairment in acute kidney injury in humans.. Nat Med 24(9):1351-1359 PMID: 30127395
- 3. Osterman I et al.. 2024. Phages reconstitute NAD(+) to counter bacterial immunity.. Nature 634(8036):1160-1167 PMID: 39322677
- 4. Zhang H et al.. 2016. NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice.. Science 352(6292):1436-43 PMID: 27127236
- 6. Elhassan YS et al.. 2019. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD(+) Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures.. Cell Rep 28(7):1717-1728.e6 PMID: 31412242
- 7. Trammell SA et al.. 2016. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans.. Nat Commun 7:12948 PMID: 27721479
- 8. Dhuguru J et al.. 2023. Defining NAD(P)(H) Catabolism.. Nutrients 15(13) PMID: 37447389
